To access this element change to forms mode OFF
Grant Award View - GA83510
MET-MED Trial: A phase III randomised double-blind placebo-controlled...
GA ID:
GA83510
Agency:
Department of Health and Aged Care
Approval Date:
14-May-2020
Publish Date:
15-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2025
Value (AUD):
$879,903.50
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF_RCRDUN_Childhood_Brain_Cancer_2020
Grant Activity:
MET-MED Trial: A phase III randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients.
Purpose:
Medulloblastoma is the most common brain cancer in children, requiring aggressive treatment to survive. Unfortunately, most patients are left with long-term brain damage, including memory and intellectual problems. Studies using metformin to promote brain repair have shown promising preliminary results. The MET-MED trial will be the first time metformin is comprehensively examined as a brain recovery agent in children diagnosed with medulloblastoma.
GO ID:
GO Title:
MRFF Clinical Trials Activity – RCRDUN Initiative – 2019 Childhood Brain Cancer Grant Opportunity
Internal Reference ID:
MRF1199289
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Clayton
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, WA, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, CANADA